Friday, May 31, 2019 1:58:44 PM
Msg 5616 of 5646 at 7/6/2016 1:54:15 PM by
jmlogan72
The following message was updated on 7/6/2016 1:57:16 PM.
TGW
Just admit I'm better at this than you:
""
egkainia • Apr 14, 2016 7:51 AM Remove
0users liked this postsusers disliked this posts17
Just going on record
To say I'm shorting this today.
I'm doing this more as a lesson to myself and to you all. Just go with the most logical, objective, emotionless decision. This is it. There is only one logical sentiment regarding NWBO--"sell."
Listen, you don't have to hold this. Anyone saying you should sell for the last 10 months has been right EVERY TIME. And every time you would all respond the same "you're not getting my shares!" or whatever other silly plot you imagined was going on. But look, no one was trying to scare you into selling to then "buy your shares on the cheap." Nope. In fact they were genuinely giving you great advice just by expressing their opinion! Imagine such a thing! You've deluded yourselves into staying long.
I admit now seems not a good time to short this. The chart is solid here, the bio sector has turned around. I'm doing this on fundamentals purely. I know they COULD have had the hold lifted. I know they don't for a negative reason. I feel strongly that this new mention in the risk factors portends something they've been considering. I think they will raise again soon at even more depressed levels. When I consider those things and look at the $1.50 price tag, I recognize the market cap is actually too high. It should be more like $50mm or so. Imo.
My opinion has been consistent here (under my other handles: Pyrrhonian, finishedworks, Michonne, jmlogan72) ever since this popped over $8 last May. I said to hedge with puts. I was ostracized and maligned. Then over $10 I said to outright sell. Again, I was in cahoots with shorts. Then I said this makes a great short ($10-$11 range). You all maligned me further. "Not getting my shares!!" Meanwhile TZOR/ryanlies was declaring he was buying more over $10... Then I finally said okay no reason to hold the short, time to close it (upper $4s). Then when Woodford came out saying what he did I said sell/short it again, though at that time I was out completely.
Now my opinion is to sell. Am I finally wrong?
""
Member when you shorted NWBO but did it all wrong?
Buy some CYTR out of the money calls. Don't be an ass.
TastytheElf has known him a long time: his iVillage is TGW
AVII
Whalatane has exchanged some messages based on his former profession.
and beyond the above, there are easily three others that have LONG; DEEP:MULTI YR
conversations with Pyrrh etc. that I could furnish.
CALMUSTANG KEY SUGGESTION since I was the first to post on THE BAKER BROTHERS: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144209272
SINCE THE BAKER BROTHERS HAVE CLOUT & INFLUENCE:
IF I were you, I would present ALL your information to them FIRST versus regulatory authorities which have CURTAILED BUDGETS! (a bureaucratic nightmare to BOOT!)
I only occasionally read some of the posts although I have been a shareholder for 4 yrs!
Everyone should buy NWBO (see my posts in May 2019):
IMHO should easily eclipse that of our AMRN.
BTW the iHub NWBO REEKS of closed minds unlike AMRN board!
Almost nigh and day respectively type compariso IMHO.
BTW: I did work at WW Hdqtrs NYC for top tiered firms as a stock analyst and as a money manager
and I do excel(nothing is beneath me) even at 70 yrs of age in my investigative skills.
Just look at North4000 at 89 yrs of age!!
CalMustang must be a graduate of CalPoly either in Pomona or SLO, CA!
DIFFERENT STROKES FOR DIFFERENT FOLKS
DIFFERENT STROKES FOR DIFFERENT FOLKS
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
